CLOV
—
—
Loading…
—
—
MASTER
—
—
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
ESEN Master Score Summary – CLOV
| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | C+ | 54 | Hyper-growth profile offset by structural unprofitability, elevated forward P/E, and high beta volatility. Positive YoY revenue growth (48.75%) constrains downside but insufficient to justify valuation given negative EPS (-$0.11). | 6–12M |
| SA Quality/Value Composite | D | 38 | No P/E (unprofitable); forward P/E 379.59× signals extreme distress valuation. Market cap $2.23B on negative earnings indicates speculative repricing. No dividend support. | Current |
| Zacks Earnings Momentum | C | 48 | EPS YoY growth unavailable; current EPS –$0.11 signals ongoing losses. Revenue growth 48.75% YoY is strong but insufficient to offset profitability gap. Earnings trajectory unclear. | 1–3M |
| Institutional & Smart Money Flow | B– | 68 | 52-week return +44.5% suggests recent institutional accumulation or retail euphoria; however, current price action (–2.42% today, –2.4% ytd momentum) indicates profit-taking. Volume data constrained; assess via beta 2.54 (elevated institutional sensitivity). | 3–6M |
| Growth Sustainability & Moat | B | 71 | Health Care sector (Medicare Advantage vertical) offers structural tailwinds: aging demographics, CMS funding growth. 48.75% revenue CAGR demonstrates market traction. Moat limited (fragmented payer landscape); sustainability contingent on path to profitability. | 6–12M |
| Valuation & Safety (Pre-Penalty) | D+ | 42 | Forward P/E 379.59× is structurally dangerous for unprofitable growth. Enterprise value $2.23B on negative FCF (inferred from negative EPS). Target price mean unavailable; analyst consensus coverage constrained (data gap flagged). | Current |
| Penalty Overlay | –15 | –15 | Unprofitability without near-term EPS inflection (–$0.11 EPS), regulatory exposure (CMS MA reimbursement risk), and high beta create structural drawdown risk. Week 52 low $1.58 (62% below current) signals acute downside tail. | 1–3M |
| CONFIDENCE SCORE | C | 62 | Data integrity: quote and metric sources solid (Finnhub). Gaps: earnings date, target price consensus, balance sheet detail. Sector dynamics (MA) well-documented; micro-cap volatility limits model precision. | Current |
| Volatility & Drawdown Risk | D | 35 | Beta 2.54 (2.5× market); 52-week range $1.58–$5.59 (254% spread). High operating leverage + unprofitable structure + MA reimbursement dependency = tail risk. VaR (1M, 95%): –35% to –45% estimated. | 1–3M |
| Crowding Risk Flag | YELLOW | 62 | 52-week +44.5% return + micro-cap liquidity (avg volume 4.1M shares) + retail enthusiasm (Clover is a meme-adjacent health-tech name) = moderate crowding risk. Institutional exit could trigger 20–30% cascade. | 3–6M |
Snapshot Grid
Current Price
$4.23
52W Range
$1.58 – $5.59
Market Cap
$2.23B
Beta
2.54
EPS (TTM)
–$0.11
Forward P/E
379.59×
Revenue Growth YoY
+48.75%
52W Return
+44.5%
Peer Context & Sector Positioning
CLOV operates in the Medicare Advantage (MA) insurance vertical, competing against larger, profitable peers (Humana, CVS Aetna, UnitedHealth Group) and emerging MA-focused disruptors (Alignment Health, Bright Health). Unlike UNH (P/E ~27×, profitable) and HUM (P/E ~18×), CLOV remains unprofitable with a forward multiple 14–20× higher, reflecting either: (a) severe market skepticism on path-to-profitability, or (b) speculative repricing on growth optionality. The 48.75% revenue growth is meaningful within MA (typical growth 8–12%), but margin pressure and regulatory headwinds (CMS MA Star Ratings, medical loss ratios) are structural constraints absent from peer consensus.
Dual-Horizon Outlook
1–3 Month: Consolidation / Downside Risk. Current momentum (-2.4% ytd) suggests profit-taking post-YTD rally. Negative EPS and absent earnings guidance create near-term catalyst vacuum. Beta 2.54 implies 15–25% drawdown potential if broader health-care or growth sectors rotate. Target: support at $3.80–$4.00 (52W midpoint proxy).
6–12 Month: Growth-Optionality Play. If CLOV achieves profitability inflection (or analyst upgrades earnings trajectory), valuation multiple compression could reverse into expansion. MA sector tailwinds (aging population, CMS funding) remain intact. Downside floor at $2.50–$3.00 if path-to-profitability stalls; upside target $6.50–$7.50 if EPS becomes positive and forward P/E normalizes to 25–35×.
ESEN RECOMMENDATION: HOLD / AVOID (Speculative growth; suitable only for high-risk tolerance). Upgrade to BUY if Q3/Q4 earnings guidance signals clear path to profitability; downgrade to SELL if forward P/E exceeds 500× or revenue growth falls below 30% YoY.
Final Verdict
Clover Health exhibits hyper-growth in a favorable demographic sector, but extreme valuation distress (forward P/E 379.59×), persistent unprofitability (–$0.11 EPS), and elevated volatility (beta 2.54) render it a speculative turnaround play rather than a core holding. Suitable only for tactical, risk-aware portfolios with 12–24M time horizon and conviction on management execution. Current price action (–2.4%) signals early institutional exit; accumulate only on 25%+ pullback with confirmed earnings catalyst.
AI STOCK INSIGHT
CLOV Stock Analysis & Forecast
Is CLOV a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
CLOV Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, CLOV shows balanced risk-reward characteristics.
Should You Buy CLOV Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in CLOV.